Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 12/20 | 0.43 |
| ▸ | AXL | P30530 | 10/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAT2A | P31153 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24878574 | 0.85 | AXL (0.38) | METAXLALDH1A1POLB | |
| SCHEMBL26084033 | 0.85 | GSK3A (0.38) | METAXLGSK3AGSK3BKDM4E | |
| SCHEMBL24878915 | 0.83 | MAPT (0.42) | METAXLALDH1A1L3MBTL1POLB | |
| SCHEMBL24878914 | 0.81 | GSK3A (0.44) | METAXLGSK3AGSK3BKDM4E | |
| SCHEMBL26756058 | 0.81 | KDM4E (0.44) | METAXLGSK3AGSK3BKDM4E | |
| SCHEMBL21785860 | 0.81 | AXL (0.36) | METAXLGSK3AGSK3BKDM4E | |
| SCHEMBL23749482 | 0.80 | ALDH1A1 (0.38) | METAXLGSK3AGSK3BKDM4E | |
| SCHEMBL21785268 | 0.79 | GSK3A (0.40) | METAXLGSK3AGSK3BKDM4E | |
| SCHEMBL23749481 | 0.77 | KDM4E (0.39) | METAXLGSK3AGSK3BKDM4E | |
| SCHEMBL14968894 | 0.76 | NOTUM (0.47) | METAXLKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780835-B2 | Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases | ARRAY BIOPHARMA INC. (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2020047184-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780835-B2 | Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases | RET, MERTK, MET | MET 3/4885AXL 20/4885GSK3A 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.